ArticleEMBO reports2023
KIAA1429/VIRMA promotes breast cancer progression by m
Open access · hybridAbstract read
In one paragraph
Article in EMBO reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 27 citations in OpenAlex.
- KIAA1429 knockdown alleviates osteosarcoma progression by destabilizing SLC7A11 mRNA via m6A methylation to promote ferroptosis.International journal of oncology · 2026Article
- KIAA1429 Stabilizes FAM84B mRNA to Enhance Colorectal Cancer Tumorigenesis via Wnt/β-Catenin Pathway.Biochemical genetics · 2026Article
- METTL3 regulates exocytosis independently of mScience advances · 2026Article
- Methylation marks breast cancer metastasis: The roles of mThe Journal of biological chemistry · 2026Review
- VIRMA modulates function of photoreceptor cells through m6A modification and alternative splicing.JCI insight · 2026Article
- Dynamic m⁶A methylation during bovine preadipocyte differentiation and functional implication of the m⁶A writer METTL14.BMC genomics · 2026Article
- The bladder cancer mEMBO reports · 2026Article
- VIRMA/IGF2BP3-mediated ANLN upregulation promotes intrahepatic cholangiocarcinoma growth by forming a positive feedback loop with RhoA/YAP1/TEAD1 signaling pathway.Cell death & disease · 2026Article
- Functional and clinical significance of the RNA mNPJ breast cancer · 2025Article
- Review
- VIRMA-mediated SHQ1 m6A modification enhances liver regeneration through an HNRNPA2B1-dependent mechanism.Acta pharmaceutica Sinica. B · 2025Article
- The mMolecular biomedicine · 2025Review
- From cell cycle control to cancer therapy: exploring the role of CDK1 and CDK2 in tumorigenesis.Medical oncology (Northwood, London, England) · 2025Review
- KIAA1429 promotes non-small-cell lung cancer cell proliferation through the TRERNA1/HOXA6 axis.Scientific reports · 2025Article
- Total m6A RNA levels and VIRMA expression as potential diagnostic and prognostic markers in oral squamous cell carcinoma.Diagnostic pathology · 2025Article
- Phosphorylation of KIAA1429 promotes oxaliplatin resistance through activating the FZD7-Wnt signaling in BRAFJournal of experimental & clinical cancer research : CR · 2025Article
- The Multifaceted Role of VIRMA, a Core Component of the Methyltransferase Complex, in Cancer and Cancer Therapy.Biomolecules · 2025Review
- Mechanism of the KIAA1429/KLF1/PD-L1 Axis in Regulating Immune Escape in Non-small Cell Lung Cancer.Cell biochemistry and biophysics · 2025Article
- The role of N6-methyladenosine (mPeerJ · 2025Review
- Exploring the Potentials of Hyaluronic Acid-coated Polymeric Nanoparticles in Enhanced Cancer Treatment by Precision Drug Delivery, Tackling Drug Resistance, and Reshaping the Tumour Micro Environment.Current medicinal chemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Na Li *Division of Genetics, Department of Pediatrics, Program in Immunology, Bioinformatics and Systems Biology Program, Institute for Genomic Medicine, La Jolla, CA, USA.ORCID 0000-0002-2852-8099
Zhouting Zhu *Division of Genetics, Department of Pediatrics, Program in Immunology, Bioinformatics and Systems Biology Program, Institute for Genomic Medicine, La Jolla, CA, USA.ORCID 0000-0001-7763-486X
Yufei DengDivision of Genetics, Department of Pediatrics, Program in Immunology, Bioinformatics and Systems Biology Program, Institute for Genomic Medicine, La Jolla, CA, USA.ORCID 0009-0000-8776-0747
Rachel TangDivision of Genetics, Department of Pediatrics, Program in Immunology, Bioinformatics and Systems Biology Program, Institute for Genomic Medicine, La Jolla, CA, USA.ORCID 0000-0003-0364-6280
Hui HuiDivision of Genetics, Department of Pediatrics, Program in Immunology, Bioinformatics and Systems Biology Program, Institute for Genomic Medicine, La Jolla, CA, USA.
Yuqi KangDivision of Genetics, Department of Pediatrics, Program in Immunology, Bioinformatics and Systems Biology Program, Institute for Genomic Medicine, La Jolla, CA, USA.
Tariq M RanaDivision of Genetics, Department of Pediatrics, Program in Immunology, Bioinformatics and Systems Biology Program, Institute for Genomic Medicine, La Jolla, CA, USA.ORCID 0000-0001-9558-5766
Center for Genomic Science · ITUniversity of California San Diego · US
Funding
Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2MVirology CoreP01CA177322 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WU, TING-TING · 2014 to 2018
$8.7MIdentification and Regulation of RNA Modification by HIV infection and MethamphetamineR01DA046171 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RANA, TARIQ M · 2018 to 2022
$3.1MIllumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600kRegulation of HIV-1 Replication by Cellular IncRNAsR21AI125103 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RANA, TARIQ M · 2016 to 2017
$426kNCI NIH HHS P01 CA177322NCI NIH HHS P30 CA030199NIAID NIH HHS R21 AI125103NIDA NIH HHS R01 DA046171NIH HHS S10 OD026929ODCDC CDC HHS S10 OD026929
Abstract
N
Indexed as
NeoplasmsCytoplasmCytosolHumansHyaluronan SynthasesRNA, MessengerHAS2 protein, humanHyaluronan SynthasesRNA, Messengerbreast cancerHAS2IGF2BP3KIAA1429/VIRMAm6A RNA modification
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.